Charilaos Samaras, Evdoxia Kyriazopoulou, Garyfallia Poulakou, Eran Reiner, Maria Kosmidou, Ioanna Karanika, Vasileios Petrakis, George Adamis, Nikolaos K. Gatselis, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, George Chrysos, Giulia Bertoli, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Evangelos Kostis, Lorenzo Dagna, Sofia Koukidou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Christina Trakatelli, George Tsoukalas, Carlo Selmi, Michael Samarkos, Athina Pyrpasopoulou, Aikaterini Masgala, Emmanouil Antonakis, Aikaterini Argyraki, Karolina Akinosoglou, Styliani Sympardi, Periklis Panagopoulos, Haralampos Milionis, Simeon Metallidis, Konstantinos N. Syrigos, Alon Angel, George N. Dalekos, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis

Cytokine 162, February 2023, 156111
DOI 10.1016/j.cyto.2022.156111

Funding

The SAVE study was funded in part by a kind donation by Technomarshipping company, in part by the Hellenic Institute for the Study of Sepsis (HISS) and in part by Sobi AB (publ). The SAVE-MORE trial was funded in part by the Hellenic Institute for the Study of Sepsis (HISS) and in part by Sobi AB (publ). Measurements of CRP, IP-10 and TRAIL for the needs of this manuscript were supported by MeMed Diagnostics, Tirat Carmel, Israel.

Keywords: Anakinra; COVID-19; IP-10; Prognosis; Respiratory failure
Related Studies: SAVE-MORE, SAVE